Telix Pharmaceuticals has entered into a strategic clinical collaboration with Varian, a Siemens Healthineers company, to ...

Credit: Getty Images The phase 3 PACE-B trial demonstrated that stereotactic body radiation therapy is noninferior to conventional radiation therapy for low- and favorable-intermediate-risk prostate ...

US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor–Positive, Unresectable or Metastatic Human Epidermal Growth Factor ...

LOS ANGELES (KABC) -- Proton therapy to treat prostate cancer has been available in Southern California for nearly 35 years. It's less invasive and offers fewer side effects compared to conventional ...

Treatments for prostate cancers localised to the prostate have long been aimed at treating the whole prostate either by ...

Proton beam therapy does not improve the patient-reported outcome of bowel function compared with IMRT. Bowel side effects do not differ between patients with localized prostate cancer who receive ...

Working with Varian, a key player in EBRT, Telix will explore how theranostics can be used more effectively by radiation oncologists to enhance patient selection and deliver targeted treatment. The ...

If you or a loved one has been diagnosed with prostate cancer, you’re not alone—and you don’t have to wait long to take the next step. Whether you’re newly diagnosed, moving from active surveillance ...

We are excited to bring the Alpha DaRT technology to prostate cancer patients in the U.S.,” said Dr. Robert B. Den, Alpha Tau ...

This satellite symposium at the European Society for Medical Oncology (ESMO) Congress 2025, chaired by Rana McKay, Professor ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patient-reported quality of life (QoL) was similar between ...